Bone Marrow Involvement in Gaucher Disease at MRI : What Long-term Evolution Can We Expect Under Enzyme Replacement Therapy?

Overview

Journal Eur Radiol

Specialty Radiology

Date 2015 Apr 16

PMID 25875285

Citations 7

Authors

Benjamin Fedida

Sebastien Touraine

Jerome Stirnemann

Nadia Belmatoug

Jean-Denis Laredo

David Petrover

Affiliations

Soon will be listed here.

Abstract

Purpose: To study the long-term evolution of the bone marrow burden (BMB) score at MRI in patients with Gaucher disease (GD) under enzyme replacement therapy (ERT).

Material And Methods: Forty patients treated for GD were retrospectively studied in a referral centre. BMB scores were assessed on spine and femur MR examinations performed between January 2003 and June 2014. The long-term evolution of the BMB scores was analyzed using a linear mixed model.

Results: A total of 121 MRI examinations were performed during the study period with a mean follow-up of 7.1 years ± 5.6, an average rate of 3.1 MR examinations ± 1.7 per patient and an interval of 2.3 years ± 1.1 between examinations. Patients had received ERT during 12 years on average ± 6.7. The trend of BMB scores with time decreased significantly by 15% (P = 0.008) during the total study period and 39% (P = 0.01) during the first 5 years of treatment. No changes in BMB scores were observed after five years of treatment.

Conclusion: In Gaucher patients, the trend of MRI BMB scores with time decreased significantly under ERT the first 5 years of treatment before a long-term stabilization.

Key Points: • Bone marrow infiltration of Gaucher patients responds to enzyme replacement therapy • MRI BMB score decreases mainly during the first five years of treatment • MRI BMB score tends to stabilize after five years of treatment • MR examinations could be limited after five years of treatment.

Citing Articles

A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study.

Bengherbia M, Berger M, Hivert B, Rigaudier F, Bracoud L, Vaeterlein O J Clin Med. 2024; 13(10).

PMID: 38792468 PMC: 11122233. DOI: 10.3390/jcm13102926.

The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy.

Zimran A, Szer J, Becker-Cohen M, Jens S, Cozma C, Revel-Vilk S J Clin Med. 2023; 12(6).

PMID: 36983221 PMC: 10054405. DOI: 10.3390/jcm12062220.

Skeletal involvement in Gaucher disease: extent of bone disease, splenic volume, and quality of life.

de Mello R, Mello M, Pessanha L, Fonseca A Radiol Bras. 2021; 54(2):71-76.

PMID: 33854259 PMC: 8029931. DOI: 10.1590/0100-3984.2020.0014.

Rare genotype associated with severe bone disease in Gaucher disease type 1.

Paskulin L, Starosta R, Zizemer V, Basgalupp S, Bertholdo D, Pinto E Vairo F Mol Genet Metab Rep. 2019; 21:100544.

PMID: 31799121 PMC: 6881662. DOI: 10.1016/j.ymgmr.2019.100544.

Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.

Degnan A, Ho-Fung V, Ahrens-Nicklas R, Barrera C, Serai S, Wang D Insights Imaging. 2019; 10(1):70.

PMID: 31289964 PMC: 6616606. DOI: 10.1186/s13244-019-0743-5.

References

Lanir A, Hadar H, Cohen I, Tal Y, Benmair J, Schreiber R . Gaucher disease: assessment with MR imaging. Radiology. 1986; 161(1):239-44. DOI: 10.1148/radiology.161.1.3763873. View

Weisstein J, Steinbach L, Diamond C, Huang S, ODonnell R . Pseudo-osteomyelitic crisis upon presentation of Gaucher disease. Skeletal Radiol. 2001; 30(7):407-10. DOI: 10.1007/s002560100369. View

Poll L, Koch J, Vom Dahl S, Willers R, Scherer A, Boerner D . Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001; 30(9):496-503. DOI: 10.1007/s002560100375. View

Masek B, Sims K, Bove C, Korson M, Short P, Norman D . Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999; 8(3):263-8. DOI: 10.1023/a:1008859420641. View

Johnson L, Hoppel B, Gerard E, Miller S, Doppelt S, Zirzow G . Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology. 1992; 182(2):451-5. DOI: 10.1148/radiology.182.2.1732964. View

Brady R, Kanfer J, Bradley R, Shapiro D . Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest. 1966; 45(7):1112-5. PMC: 292783. DOI: 10.1172/JCI105417. View

Magnaldi S, Longo R, Ukmar M, Zanatta M, Bottega M, Sottocasa G . Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy. Eur Radiol. 1997; 7(4):486-91. DOI: 10.1007/s003300050189. View

Elstein D, Haims A, Zahrieh D, Cohn G, Zimran A . Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up. Blood Cells Mol Dis. 2014; 53(1-2):56-60. DOI: 10.1016/j.bcmd.2014.02.006. View

Weinreb N, Andersson H, Banikazemi M, Barranger J, Beutler E, Charrow J . Prevalence of type 1 Gaucher disease in the United States. Arch Intern Med. 2008; 168(3):326-7. DOI: 10.1001/archinternmed.2007.128. View

10.

Barton N, Brady R, Dambrosia J, Di Bisceglie A, Doppelt S, Hill S . Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991; 324(21):1464-70. DOI: 10.1056/NEJM199105233242104. View

11.

Beutler E, Nguyen N, Henneberger M, Smolec J, McPherson R, West C . Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet. 1993; 52(1):85-8. PMC: 1682129. View

12.

Yossipovitch Z, Herman G, Makin M . Aseptic osteomyelitis in Gaucher's disease. Isr J Med Sci. 1965; 1(4):531-6. View

13.

Brady R, Barton N . Enzyme replacement and gene therapy for Gaucher's disease. Lipids. 1996; 31 Suppl:S137-9. DOI: 10.1007/BF02637065. View

14.

Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H . Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis. 2002; 27(6):1005-12. DOI: 10.1006/bcmd.2001.0474. View

15.

Kamath R, Lukina E, Watman N, Dragosky M, Pastores G, Arreguin E . Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014; 43(10):1353-60. PMC: 4141971. DOI: 10.1007/s00256-014-1891-9. View

16.

Grabowski G . Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008; 372(9645):1263-71. DOI: 10.1016/S0140-6736(08)61522-6. View

17.

de Fost M, van Noesel C, Aerts J, Maas M, Poll R, Hollak C . Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica. 2008; 93(7):1119-20. DOI: 10.3324/haematol.12651. View

18.

Charrow J, Andersson H, Kaplan P, Kolodny E, Mistry P, Pastores G . The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000; 160(18):2835-43. DOI: 10.1001/archinte.160.18.2835. View

19.

Vazquez A, Bates D, Rosa G, Gianola D, Weigel K . Technical note: an R package for fitting generalized linear mixed models in animal breeding. J Anim Sci. 2009; 88(2):497-504. DOI: 10.2527/jas.2009-1952. View

20.

Meikle P, Hopwood J, Clague A, Carey W . Prevalence of lysosomal storage disorders. JAMA. 1999; 281(3):249-54. DOI: 10.1001/jama.281.3.249. View